VIDEO: Sozinibercept shows good results in combination with VEGF-A inhibitors

ByDante J. Pieramici, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dante J. Pieramici, MD, overviews pharmacokinetics and safety data for sozinibercept.

Sozinibercept (Opthea), formerly known as OPT-302, is a VEGF-C/D “trap” inhibitor that has demonstrated improved vision and anatomic outcomes in patients with wet age-related macular degeneration when used in combination with VEGF-A inhibitors, according to Pieramici.

“This drug seems to be very safe when used in combination,” he said. “There was really no additional ocular or systemic safety events with the combination approach compared to a monotherapy approach.”

Published by:

Sources/Disclosures

Collapse

Source:

Pieramici DJ. Population pharmacokinetics and safety of OPT-302, an anti-VEGF-C/-D “trap”, in patients with retinal vascular diseases. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.

Disclosures: Pieramici reports being an advisor for and having received research funding from Opthea.

American Society of Retina Specialists Meeting

Read more

VIDEO: Sozinibercept shows good results in combination with VEGF-A inhibitors

Related Content